Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients | Zendy

M.-C. Quinton | Zendy; Sandra Bodeau | Zendy; Loay Kontar | Zendy; Yoann Zerbib | Zendy; Julien Maizel | Zendy; Michel Slama | Zendy; Kamel Masmoudi | Zendy; AnneSophie LemaireHurtel | Zendy; Youssef Bennis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neurotoxic Concentration of Piperacillin during Continuous Infusion in Critically Ill Patients

Author(s) -

M.-C. Quinton,

Sandra Bodeau,

Loay Kontar,

Yoann Zerbib,

Julien Maizel,

Michel Slama,

Kamel Masmoudi,

AnneSophie LemaireHurtel,

Youssef Bennis

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00654-17

Subject(s) - piperacillin , medicine , intensive care unit , piperacillin/tazobactam , retrospective cohort study , neurotoxicity , critically ill , continuous infusion , anesthesia , cohort , intensive care , intensive care medicine , toxicity , biology , genetics , bacteria , pseudomonas aeruginosa

This retrospective cohort study included 53 patients admitted to the intensive care unit (ICU), with an average age of 69 years, without neurologic disorder before initiation of a continuous piperacillin infusion at the standard dose and who underwent piperacillin serum concentration monitoring. Among them, 23 developed a neurologic disorder for which the piperacillin causality was chronologically and semiologically suggestive. A concentration threshold of 157.2 mg/liter independently predicted neurotoxicity with 96.7% specificity and 52.2% sensitivity and may constitute a limitation when targeting less susceptible pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research